Ibogaine for Health & Longevity
Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: Ibogaine HCl, Ibogaine Hydrochloride, 12-methoxyibogamine, DMX-1002
Motivation
Ibogaine is a naturally occurring psychoactive compound found in the root bark of the West African shrub Tabernanthe iboga, and it can also be made from related plant compounds. It acts on several brain signaling systems at once and produces a dream-like state lasting many hours. Interest in ibogaine spans addiction medicine, trauma-related conditions and brain injury, all of which touch on long-term brain health and overall well-being.
Ibogaine has been used ritually in Gabon for generations and, since the 1960s, informally in clinics and self-help settings, mostly outside the United States, where it is a banned controlled substance. Recent years brought renewed attention: universities have studied it in veterans, and some governments have set aside funding for research. It is typically given as a single supervised session rather than as a daily regimen.
This review examines the human evidence on ibogaine for health and longevity, given growing research and public interest: what has been studied, how strong the data are, the safety data with attention to the heart, how supervised sessions are structured, and what ongoing trials may add. It presents the evidence for and against without recommending its use.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The following expert commentary and scientific articles give a high-level overview of ibogaine.
-
Dr. Nolan Williams: Psychedelics & Neurostimulation for Brain Rewiring - Andrew Huberman
Roughly 12-minute segment on ibogaine’s “life review” experience and its early clinical trials for trauma and depression, within a wider discussion of psychedelics and brain stimulation with a Stanford psychiatrist.
-
Magnesium-ibogaine therapy in veterans with traumatic brain injuries. - Cherian et al., 2024
Study without a comparison group of 30 veterans with blast-related brain injury treated with ibogaine plus magnesium. Several co-authors are affiliated with the treating clinic (Ambio Life Sciences), a financial interest.
-
Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives. - Kervadec et al., 2026
Narrative review (non-systematic expert summary) of clinical studies from 1990 to 2025 concluding that most positive findings come from uncontrolled studies (without a comparison group) and that current evidence does not support clinical use.
-
How toxic is ibogaine? - Litjens & Brunt, 2016
Toxicology review of ibogaine’s pharmacology, effects on coordination and the heart, and reported deaths, including cases without prior cardiac disease.
Note: Only four items qualified, so the list is not padded. The only Rhonda Patrick (FoundMyFitness) result is a two-minute news digest of one combined-psychedelic study without expert commentary, so it is not listed. No relevant ibogaine content was found from Peter Attia (site search returned two general psychedelics episodes whose public pages do not discuss ibogaine), Chris Kresser (no results), Life Extension (no ibogaine content located) or Lifespan.io (only a passing mention in a 2023 article on psychedelics and Alzheimer’s disease).
Grokipedia
AI-generated encyclopedia entry covering ibogaine’s chemistry, pharmacology, preparations, cardiac risks and legal status; useful for orientation, but its claims require checking against primary sources.
Examine
No Examine article on ibogaine exists.
ConsumerLab
No dedicated ConsumerLab article on ibogaine exists; its only related item is a 2015 Recalls & Warnings notice on an unauthorized product containing ibogaine (see Sourcing and Quality).
Systematic Reviews
Systematic reviews (structured literature syntheses) and meta-analyses (pooled statistical analyses of several studies) of ibogaine were selected from PubMed for relevance, scope and recency, covering both effects and risks.
-
A systematic literature review of clinical trials and therapeutic applications of ibogaine. - Köck et al., 2022
Review of 24 clinical studies (705 people): reduced withdrawal symptoms and craving, alongside severe complications and deaths linked to heart and nervous system toxicity.
-
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. - Mosca et al., 2023
31 studies plus a meta-analysis of side effects: some efficacy in substance use disorders, concerning heart toxicity and mortality, and significantly more headaches.
-
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020). - Ona et al., 2022
Updated review of 18 studies (2015–2020) on adverse events, mainly acute cardiac, persistent psychiatric and neurological signs; ICEERS-affiliated authors (nonprofit promoting iboga use).
-
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies. - Rocha et al., 2023
Review of 12 sources concluding controlled settings with medical, psychiatric and cardiac monitoring are essential for safer administration; ICEERS-affiliated authors (nonprofit promoting iboga use).
-
Ibogaine and addiction in the animal model, a systematic review and meta-analysis. - Belgers et al., 2016
Meta-analysis of 27 animal studies: ibogaine reduced drug self-administration, especially within 24 hours, but caused motor impairment and cerebral cell loss; animal-only evidence.
Mechanism of Action
Ibogaine is a plant alkaloid (nitrogen-containing plant compound) that binds many targets, each weakly to moderately, not one selective receptor. Actions include blocking NMDA receptors (glutamate receptors involved in learning and craving circuits) (Popik et al., 1995) and, through its active breakdown product noribogaine, biased activation of kappa-opioid receptors (opioid receptors modulating stress and reward) (Maillet et al., 2015, authors at DemeRx, an ibogaine drug developer). The liver enzyme CYP2D6 (an enzyme that clears many drugs) makes noribogaine from ibogaine (Obach et al., 1998). Ibogaine has a half-life (time for blood concentration to halve) of about 7.5 hours (a drug-reference monograph), whereas noribogaine’s is 24–30 hours (Glue et al., 2016, sponsored by the same developer) and enters the brain in rodents (Mash et al., 2016, authors at the same developer).
Explanations compete. The pharmacological view attributes effects to receptor and transporter actions plus higher neurotrophic factors (GDNF and BDNF; proteins supporting neuron survival and neuroplasticity, the brain’s capacity to rewire) in rats (Marton et al., 2019). The experiential view holds that the prolonged dream-like “life review” drives benefit: in veterans, more intense mystical experiences accompanied larger reductions in post-traumatic stress symptoms (Brown et al., 2026).
Cardiac effects arise from blockade of the hERG potassium channel (which resets heart muscle after each beat) by ibogaine and noribogaine at similar potency (Alper et al., 2016), seen as QTc prolongation (corrected QT interval: the heart’s electrical recharge time). One study tied QTc changes to ibogaine rather than noribogaine (Knuijver et al., 2024).
Historical Context & Evolution
Ibogaine originates from the root bark of Tabernanthe iboga, a shrub of West Central Africa. Traditionally, low doses combated fatigue, hunger and thirst, and high doses served as a sacrament in ritual contexts (Mash, 2023, authored by a DemeRx founder). Its use for addiction began in the 1960s, when American and European self-help groups reported that a single dose relieved drug craving and opioid withdrawal (Mash, 2023). By 2006, an estimated 3,414 people outside the traditional religion had taken it, 53% for opioid withdrawal (Alper et al., 2008), and a 2005 report in Science called the practice a “vast, uncontrolled experiment” (Vastag, 2005).
Interest in health optimization is more recent. Reports that one treatment might reset addiction, and later ease trauma and brain-injury symptoms in veterans (Cherian et al., 2024), placed ibogaine within the wider revival of psychedelic research. Longevity interest is indirect: no study identified in this review examined lifespan, and the appeal rests on brain health, trauma recovery and addiction-related harm.
Opinion has moved in two directions. Heart-safety data from a Dutch study (Knuijver et al., 2022) and toxicology reviews (Litjens & Brunt, 2016) tempered early enthusiasm, while magnesium co-administration, monitored settings and state-funded trials renewed it. A 2026 review judged the evidence insufficient for clinical use (Kervadec et al., 2026); a systematic review argued that controlled settings are essential for safety (Rocha et al., 2023, ICEERS-affiliated, a nonprofit promoting iboga use). Both positions rest on largely uncontrolled data, so the current standing remains open.
Expected Benefits
For health-optimizing adults, the relevant question is whether findings from disease populations transfer; every benefit below was studied in people with addiction, trauma-related conditions or brain injury.
High 🟩 🟩 🟩
No benefit reaches High: the human data are uncontrolled cohorts (groups followed over time without a comparison group), retrospective analyses (reviews of past records) and small dose-escalation studies (stepwise dose increases), and no outcome has been replicated in more than one controlled trial.
Medium 🟩 🟩
No benefit reaches Medium: the only placebo-controlled results are one small unreplicated cocaine trial and one inconclusive noribogaine trial, and the remaining human data are uncontrolled.
Low 🟩
Trauma, Mood, Anxiety, Disability and Suicidal-Thought Reduction in Veterans with Brain Injury
In 30 veterans with mostly mild blast-related traumatic brain injury (TBI), magnesium-ibogaine treatment preceded lower post-traumatic stress disorder (PTSD, persistent distress after trauma), depression, anxiety and disability scores and fewer suicidal thoughts (Cherian et al., 2024); an 86-veteran program showed smaller gains (Davis et al., 2023). Both were uncontrolled.
Magnitude: At one month, PTSD scores fell from 31.7 to 4.8 (Cohen’s d, a standardized effect size, of 2.54), depression from 25.6 to 3.8, anxiety from 20.8 to 3.9 and disability from 30.2 to 5.1; 86% met PTSD remission criteria (symptoms below a clinical cutoff), and the share reporting suicidal thoughts fell from 47% to 7% in an exploratory analysis (Cherian et al., 2024).
Reduced Substance Dependence and Opioid Withdrawal ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
Uncontrolled series report eased opioid withdrawal and lower substance use (Brown & Alper, 2018); one small placebo-controlled trial reported reduced cocaine-dependence symptoms (Mosca et al., 2023), whereas developer-sponsored noribogaine showed only a non-significant trend (Glue et al., 2016). Bears on addiction, not longevity. Net reading: signals are unreplicated.
Magnitude: In 30 people, withdrawal scores fell from 31.0 to 14.0 (about 55%) roughly 76 hours after treatment, and 50% reported no opioid use in the prior 30 days at one month, sustained to 12 months at levels below the one-month effect (Brown & Alper, 2018); a 191-person open-label series (patients and clinicians knew the treatment given; by a DemeRx founder) likewise reported reduced withdrawal and craving, without an outcome figure in its abstract (Mash et al., 2018). In 75 alcohol, cannabis, cocaine and crack users, median (middle-value) abstinence was 5.5 months after one treatment and 8.4 months after several (Schenberg et al., 2014, authors affiliated with the Brazilian treatment clinic). In the cocaine trial, 20 men given 1800 mg had significantly reduced dependence symptoms versus placebo; the reviews report no outcome figure, and a narrative review notes it is unreplicated (Mosca et al., 2023; Kervadec et al., 2026). A 2026 pilot in 9 adults with alcohol use disorder reported reduced alcohol consumption, but only five completed it (Rocha et al., 2026, co-authors affiliated with ICEERS, a nonprofit promoting iboga use).
Cognition, Sleep and Post-Concussion Symptom Improvement
In veterans given ibogaine plus a second psychedelic, self-reported insomnia, post-concussion symptoms (lingering headache and dizziness after head injury) and cognitive functioning improved at one month (Davis et al., 2023). Testing in the magnesium-ibogaine cohort showed faster processing and better problem-solving (Cherian et al., 2024). Both were uncontrolled.
Magnitude: Cohen’s d was 0.35 for insomnia, 0.39 for post-concussion symptoms and 0.27 for cognitive functioning at one month (Davis et al., 2023); processing speed reached 1.34 (Cherian et al., 2024).
Speculative 🟨
Neuroplasticity and Brain-Age Markers
Scans of 25 uncontrolled veterans showed a thicker outer brain layer and 1.3-year-lower predicted brain age (Geoly et al., 2026); rats show neurotrophic factor changes (Marton et al., 2019). Basis: imaging and animal data.
Benefit-Modifying Factors
- Genetics: CYP2D6 genotype changes ibogaine clearance (Knuijver et al., 2024), but exposure did not correlate with withdrawal severity; no genotype has been shown to predict benefit.
- Baseline biomarkers: No blood or imaging marker has been shown to predict response; trials use baseline symptom scores as the reference for change.
- Sex: Cohorts were largely male (all 30 veterans in Cherian et al., 2024); one New Zealand cohort was 50% female (Noller et al., 2018, a co-author employed by MAPS, a nonprofit funding psychedelic research). No sex-stratified benefit analysis was found.
- Pre-existing conditions: Reported benefits come from people with treatment-resistant addiction, PTSD or brain injury; several veterans relapsed after psychosocial stressors on returning home (Cherian et al., 2024).
- Age: Studied adults averaged about 43 (Davis et al., 2023) to 45 years (Cherian et al., 2024); no benefit data exist for adults in their late sixties or older.
- Subjective experience: More intense mystical experiences accompanied larger PTSD reductions (Brown et al., 2026), suggesting the quality of the session may modify benefit.
Potential Risks & Side Effects
For risk-aware adults considering a supervised session, event rates (how often an event occurs) come from patient populations; deaths clustered in people with cardiac disease or other substances, so the absolute risk (chance of an event in a defined group) in screened adults with healthy hearts is unquantified.
High 🟥 🟥 🟥
QT Prolongation, Arrhythmia and Sudden Cardiac Death ⚠️ Conflicted
Ibogaine and noribogaine block the hERG potassium channel, delaying heart recovery (QTc prolongation) and enabling arrhythmias (irregular heartbeats), including torsades de pointes (a life-threatening rhythm) and bradycardia (slow heart rate). Prolongation appeared in a noribogaine trial (Glue et al., 2016) and a Dutch series (Knuijver et al., 2022), and 19 deaths were reviewed (Alper et al., 2012); a magnesium-treated Stanford cohort reported none (Cherian et al., 2024). Net reading: prolongation is frequent, and its absence under magnesium is unreplicated.
Magnitude: In 14 patients given 10 mg/kg, the largest QTc rise averaged 95 milliseconds (ms; range 29–146), 50% exceeded 500 ms and no torsades occurred (Knuijver et al., 2022); noribogaine raised QTc by 0.17 ms per ng/mL, about 42 ms at 180 mg (Glue et al., 2016).
Nausea, Vomiting and Headache
Nausea, vomiting and headache are common during the session (a drug-reference monograph lists vomiting among frequent mild effects); the mechanism is not established. In the Stanford magnesium-ibogaine cohort they required treatment (Cherian et al., 2024), and pooled analysis found a significantly higher headache risk after ibogaine or noribogaine (Mosca et al., 2023). Effects were transient and non-serious.
Magnitude: 40% of 30 veterans were treated for headache and 23% for nausea during the session (Cherian et al., 2024).
Cerebellar Ataxia and Tremor
Transient loss of coordination (ataxia) and tremor occur, consistent with effects on the cerebellum (the balance and coordination center); falls are the practical hazard. All 30 veterans had mild ataxia and intention tremor (tremor on purposeful movement) resolving within 24 hours (Cherian et al., 2024), while all 14 Dutch patients had severe transient ataxia (Knuijver et al., 2022).
Magnitude: Ataxia occurred in 14 of 14 patients (severe, unable to walk unaided) at 10 mg/kg and in 30 of 30 veterans (mild) at about 12 mg/kg (Knuijver et al., 2022; Cherian et al., 2024).
Medium 🟥 🟥
Acute Anxiety, Agitation and Insomnia
Psychological distress, restlessness and insomnia can accompany the prolonged session and its aftermath; the mechanism is not established. Ten percent of veterans needed treatment for anxiety and 3% for insomnia (Cherian et al., 2024); in a 2026 alcohol pilot, two of nine participants needed medication for agitation, insomnia and hypertension (high blood pressure) (Rocha et al., 2026). Data are uncontrolled and small.
Magnitude: 3 of 30 veterans needed treatment for anxiety and 1 of 30 for insomnia (Cherian et al., 2024).
Blood Pressure Elevation
Mild to moderate blood pressure rises occur around dosing; the mechanism is not established. Two of 30 veterans needed treatment for hypertension (high blood pressure) (Cherian et al., 2024), and mild to moderate blood pressure alterations were seen in a 2026 pilot (Rocha et al., 2026). Trials exclude uncontrolled hypertension.
Magnitude: 7% (2 of 30) of veterans were treated for hypertension during the session (Cherian et al., 2024).
Low 🟥
Overdose Risk After Stopping Maintenance Medication
Programs often require stopping methadone or buprenorphine (opioid maintenance medications) before ibogaine. Commentary warns that replacing these mortality-reducing medications with an unproven treatment could raise overdose risk for some people (Terasaki et al., 2026). The basis is expert commentary from addiction medicine, whose practitioners prescribe these medications, not outcome data.
Magnitude: Not quantified in available studies. No study has measured overdose rates after ibogaine, and the concern rests on commentary and on the general risk of discontinuing maintenance medication.
Persistent Psychiatric Effects, Including Mania
An ICEERS-affiliated (nonprofit promoting iboga use) adverse-event review found long-lasting psychiatric signs (Ona et al., 2022); a drug-reference monograph describes manic episodes (elevated, agitated mood) lasting one to two weeks. Trials exclude psychosis (loss of contact with reality) and bipolar disorder (alternating manic and depressive episodes). Reports are case-based.
Magnitude: Not quantified in available studies. Evidence consists of case reports and small series that do not report how many people were exposed, so incidence (how often it occurs) is unknown.
Seizures
Seizures have been reported after ibogaine intoxication (Breuer et al., 2015) and in fatalities linked to withdrawal from alcohol or benzodiazepines (sedatives) (Alper et al., 2012). Seizure history is a trial exclusion. Evidence is limited to case reports.
Magnitude: Not quantified in available studies. Only case reports and forensic case series exist, without the number of people exposed needed to calculate incidence (how often it occurs).
Visual Disturbance and Transient Confusion
Visual hallucinations and mild confusion accompany the dream-like session; the mechanism is not established. A drug-reference monograph lists confusion among frequent mild effects, and pooled placebo-controlled trials showed borderline visual impairment (Mosca et al., 2023). A Dutch series found no delirium (acute confusion) above threshold (Knuijver et al., 2022).
Magnitude: The risk difference (absolute difference in event rates) for visual impairment was 0.21 (95% confidence interval, the range likely to contain the true value: 0.00 to 0.42; p = 0.05, the probability of a result at least this large arising by chance alone), pooling one ibogaine and one noribogaine trial (Mosca et al., 2023).
Speculative 🟨
Cerebellar Neuron Loss
High doses in rats cause Purkinje cell (cerebellar neuron) loss, absent below 25 mg/kg; human autopsies show no characteristic neurotoxic syndrome (toxicology review Litjens & Brunt, 2016; Alper et al., 2012). Basis: animal data.
Risk-Modifying Factors
- Genetics: Volunteers with CYP2D6 blocked by paroxetine (mimicking poor metabolizers, people with little or no CYP2D6 activity) had about twice the active-compound exposure (Glue et al., 2015); clearance tracked genotype (Knuijver et al., 2024).
- Baseline biomarkers: Resting QTc above 420 ms or heart rate below 50 beats per minute excludes participants from a registered trial (NCT05029401, sponsored by atai Therapeutics, an ibogaine developer); low potassium or magnesium raises arrhythmia risk generally.
- Sex: No ibogaine-specific sex analysis was found; women face higher risk of drug-induced torsades in general (Makkar et al., 1993). Four of 19 reviewed fatalities were women (Alper et al., 2012).
- Pre-existing conditions: Cardiovascular disease, psychiatric disorders, seizure history, and alcohol or benzodiazepine dependence were linked to deaths or adverse events (Alper et al., 2012).
- Age: Reviewed fatalities occurred at ages 24–54; trials cap enrollment at 55 (NCT05029401) or 70 (Cherian et al., 2024), so safety in older adults is undocumented.
Key Interactions & Contraindications
Prescription drugs
- QT-prolonging drugs (methadone, citalopram, haloperidol, ondansetron, azithromycin, amiodarone): contraindicated; additive QT prolongation may cause torsades or cardiac arrest. A registered trial excludes any such drug in the prior 28 days (NCT05029401).
- CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine; drugs that block CYP2D6): contraindicated; roughly double active-compound exposure with paroxetine (Glue et al., 2015). Washout precedes dosing, and long-acting agents such as fluoxetine need longer.
- Serotonin-raising drugs (sertraline, escitalopram, duloxetine, tramadol, phenelzine): contraindicated; risk of serotonin syndrome (dangerous serotonin excess causing agitation, fever, tremor). The treating clinic in the Stanford study required discontinuation (Cherian et al., 2024).
- Beta-blockers (metoprolol, propranolol; heart-rate-lowering drugs) and calcium-channel blockers (verapamil, diltiazem; blood pressure drugs): caution; additive bradycardia and low blood pressure. The same clinic required discontinuation (Cherian et al., 2024).
- Diuretics (furosemide, hydrochlorothiazide; water-excreting drugs) and corticosteroids (prednisone; anti-inflammatory hormones): contraindicated in the Stanford program (Cherian et al., 2024); potassium and magnesium loss raises torsades risk. Electrolytes are corrected beforehand.
- Opioids (heroin, oxycodone, buprenorphine; methadone is listed above as QT-prolonging): caution; unmanaged withdrawal can be severe, and stopping maintenance medication may raise overdose risk. The Dutch protocol first converted patients to morphine (Knuijver et al., 2022).
- Benzodiazepines (diazepam, alprazolam; sedatives) and alcohol: caution; withdrawal seizures were implicated in fatalities (Alper et al., 2012). Medically managed withdrawal is completed first.
- Stimulants (amphetamine, methylphenidate; drugs that raise alertness and heart rate): contraindicated in the Stanford program (Cherian et al., 2024); additive blood pressure and heart rate rises.
Over-the-counter medications
- QT- or CYP2D6-active products (loperamide at high doses, diphenhydramine, dextromethorphan, cimetidine; products that lengthen the QT interval or alter CYP2D6 activity): caution; possible added QT prolongation or higher ibogaine exposure. Protocols stop them before dosing.
- Decongestants (pseudoephedrine, phenylephrine; nasal-congestion relievers): caution; raise blood pressure and heart rate, so they are withheld around dosing.
Supplements
- Serotonin-raising supplements (St. John’s wort, 5-hydroxytryptophan, L-tryptophan, S-adenosylmethionine): contraindicated; serotonin syndrome risk. Protocols discontinue them before dosing.
- Licorice root: contraindicated; lowers potassium, adding torsades risk.
- Kratom (mitragynine): contraindicated; opioid-like activity and possible CYP2D6 inhibition complicate dosing and withdrawal.
- Cannabidiol and berberine: caution; possible CYP2D6 inhibition of uncertain clinical size, so they are stopped before dosing.
Supplements with additive effects
- Stimulant supplements (yohimbine, synephrine, high-dose caffeine): contraindicated; additive blood pressure and heart rate rises.
- Magnesium and potassium: monitor; the Stanford protocol gave intravenous magnesium sulfate to counter QT prolongation, though without a comparison group (Cherian et al., 2024); oral supplements have not been shown to replace monitored dosing.
Other interventions
- Grapefruit and Seville orange: caution; possible enzyme-mediated changes in exposure (mechanism unconfirmed), and a registered trial excluded citrus (NCT05029401).
- Other psychedelics (psilocybin, 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT, a short-acting psychedelic]): caution; combined programs exist (Davis et al., 2023), but additive cardiovascular and psychological effects are possible and interaction data are lacking.
- Fasting, dehydration and heat exposure: caution; electrolyte shifts could increase QT risk (mechanistic inference), so hydration and electrolytes are maintained.
Populations who should avoid Ibogaine:
- Congenital or acquired long QT syndrome (a heart-rhythm disorder), family history of sudden cardiac death, or resting QTc above 420 ms
- Structural or ischemic (reduced blood supply) heart disease, heart failure, arrhythmias, or syncope (fainting) of unknown cause
- Resting heart rate below 50 beats per minute, or blood pressure at or above 160/100 mmHg
- Uncorrected hypokalemia (low potassium) or hypomagnesemia (low magnesium)
- Personal or first- or second-degree family history of psychosis, bipolar disorder or schizophrenia (a chronic psychotic disorder)
- Seizure history, or recent alcohol or benzodiazepine dependence without medically managed withdrawal
- Liver or kidney disease (excluded from the Stanford study; Cherian et al., 2024)
- Pregnancy or lactation (no safety data)
- CYP2D6 poor metabolizers at standard doses (some protocols exclude poor and ultra-rapid metabolizers, people with unusually high CYP2D6 activity)
- Active suicidal ideation (current thoughts of suicide or self-harm)
- Anyone taking interacting drugs that cannot be safely stopped
Risk Mitigation Strategies
- Cardiac screening before dosing: protocols require a 12-lead electrocardiogram (ECG, heart tracing) with QTc at or below 420 ms and no long QT history; this mitigates arrhythmia risk (NCT05029401).
- Intravenous magnesium: the Stanford protocol gave 1 g magnesium sulfate before dosing and an additional dose about 12 hours later to counter QT prolongation (Cherian et al., 2024).
- Continuous ECG monitoring for at least 24 hours: QTc stayed above 450 ms beyond 24 hours in 6 of 14 patients, so shorter observation misses delayed arrhythmia risk (Knuijver et al., 2022).
- Trained staff and resuscitation capability: the Stanford program used advanced cardiac life support-certified staff at a ratio of one per two patients, mitigating cardiac arrest (Cherian et al., 2024).
- Weight-based dosing with a test dose: a 2–3 mg/kg test dose, then further doses to under 14 mg/kg total over about 2 hours, limits overexposure and QTc excursions (Cherian et al., 2024).
- CYP2D6 genotyping and dose halving: reducing the dose by half in poor metabolizers offsets doubled exposure and its cardiac and cerebellar effects (Glue et al., 2015).
- Medication washout: stopping QT-prolonging and CYP2D6-inhibiting drugs 28 days beforehand prevents raised exposure and additive arrhythmia risk (NCT05029401).
- Electrolyte correction: normalizing potassium and magnesium before dosing lowers torsades risk, since low levels of either increase arrhythmia susceptibility generally.
- Opioid conversion before treatment: the Dutch protocol converted patients to short-acting morphine before dosing, limiting uncontrolled withdrawal from long-acting opioids during monitoring (Knuijver et al., 2022).
- Fall precautions for 24 hours: assisted walking and bed-level supervision mitigate injury from ataxia lasting up to 24 hours.
- Psychiatric screening and integration support: excluding psychosis histories and providing pre- and post-treatment coaching mitigates psychiatric destabilization and relapse (Cherian et al., 2024).
- Pharmaceutical-grade product: the Stanford protocol used ibogaine hydrochloride of at least 98% purity (Cherian et al., 2024), limiting exposure to co-occurring alkaloids that also block the hERG channel (Alper et al., 2016).
Therapeutic Protocol
- Stanford magnesium-ibogaine protocol: 8-hour fast, then a 2–3 mg/kg test dose and further doses after about 40 minutes, up to under 14 mg/kg within 2 hours, with intravenous magnesium and 12–16 hours of ECG monitoring (Cherian et al., 2024).
- Dutch inpatient protocol: conversion to morphine, then a single 10 mg/kg dose with at least 24 hours of monitoring of QTc, blood pressure, ataxia and delirium (acute confusion) (Knuijver et al., 2022).
- Repeated fixed-dose approach: a registered Spanish trial, sponsored by ICEERS (a nonprofit promoting iboga use), gave 100 mg doses (up to 600 mg) stepwise as withdrawal returned, to taper methadone (NCT04003948).
- Ibogaine with psychotherapy, repeated sessions: a Brazilian clinic combined ibogaine with psychotherapy, and repeated treatments were associated with longer abstinence (Schenberg et al., 2014).
- Traditional root-bark preparations: ritual use in Gabon relies on whole root bark containing a mixture of alkaloids, distinct from purified hydrochloride; uninformed use of such forms was a risk factor in fatalities (Alper et al., 2012).
- Expert and clinic attribution: the Stanford Brain Stimulation Lab (Nolan Williams) led the magnesium-ibogaine study, treatment being delivered at Ambio Life Sciences, Mexico (Cherian et al., 2024).
- Time of day: the Stanford treatment began on the evening of day 2 and continued through day 3 (Cherian et al., 2024); no study compared timing.
- Half-life: ibogaine’s half-life is about 7.5 hours (a drug-reference monograph), while noribogaine’s is 24–30 hours, so effects and QT risk outlast the subjective session (Glue et al., 2016).
- Single versus split doses: the Stanford protocol split dosing over 2 hours, with a 4 mg/kg booster after 12 hours in one participant; the Dutch protocol used one dose (Cherian et al., 2024).
- Genetic polymorphisms: CYP2D6 activity predicts ibogaine clearance; genotyping and halving the dose in poor metabolizers has been proposed (Glue et al., 2015).
- Sex differences: no sex-specific dosing data exist; cohorts were mostly male, and female sex raises baseline torsades susceptibility generally (Makkar et al., 1993).
- Age: protocols enrolled adults up to 55 or 70 years; no dosing data exist for older adults.
- Baseline biomarkers: QTc, potassium, magnesium, heart rate and blood pressure determine eligibility rather than dose (NCT05029401).
- Pre-existing conditions: cardiac, seizure, psychotic and severe liver conditions exclude dosing; substance dependence requires stabilization or withdrawal management first.
Discontinuation & Cycling
- Duration: ibogaine is administered as a single supervised session or a short series, not as a lifelong regimen; the reviewed programs assessed outcomes for up to 12 months (Noller et al., 2018).
- Withdrawal effects: physical dependence on ibogaine itself was not reported in the studies reviewed; the practical withdrawal issue is opioid or alcohol withdrawal that ibogaine is used to manage.
- Tapering: ibogaine is not tapered; interacting drugs such as antidepressants require supervised tapering beforehand, and maintenance opioids are converted or stopped before dosing (Knuijver et al., 2022).
- Symptom recurrence: some veterans had notable symptom recurrence between the immediate and one-month assessments, often after psychosocial stressors (Cherian et al., 2024).
- Repeat treatments and cycling: no cycling schedule or minimum interval is established; multiple treatments were associated with longer abstinence in one analysis (Schenberg et al., 2014), while each session repeats the cardiac exposure.
Sourcing and Quality
- Product forms: purified ibogaine hydrochloride, total-alkaloid extracts and root bark differ in composition; the Stanford study used 98+% pure hydrochloride semi-synthesized from voacangine of Voacanga africana (Cherian et al., 2024).
- Purity and analog content: semisynthetic and plant-extracted ibogaine blocked hERG channels at similar potency, while voacangine and noribogaine were similarly or more potent, so alkaloid impurities matter (Alper et al., 2016).
- What to look for: a certificate of analysis giving ibogaine content, identified impurities, botanical or synthetic origin, and independent third-party testing; no official quality standard exists.
- Unauthorized products: Health Canada linked abnormal heart rhythms to an unauthorized natural product containing ibogaine (Abnormal Heart Rhythms Linked with Unauthorized Natural Product, Health Canada Warns).
- Providers and pharmacies: no approved product or compounding pharmacy exists in the United States; study sites include Ambio Life Sciences in Mexico (Cherian et al., 2024) and a Dutch university clinic (Knuijver et al., 2022). These are research sites, not endorsements.
Practical Considerations
- Time to effect: withdrawal scores fell within about 76 hours (Brown & Alper, 2018); psychiatric scale improvements appeared at 4–5 days and one month (Cherian et al., 2024).
- Common pitfalls: stopping maintenance medication abruptly (a concern raised in commentary from addiction medicine, whose practitioners prescribe it; Terasaki et al., 2026), unmonitored settings (Rocha et al., 2023, ICEERS-affiliated, promoting iboga use), unverified products, and omitting aftercare, since relapses followed stressors at home.
- Regulatory status: ibogaine is a Schedule I substance (no accepted medical use, high abuse potential) in the United States; treatment occurs in jurisdictions such as Mexico (Cherian et al., 2024) and New Zealand (Noller et al., 2018).
- Public funding: Texas committed $50 million to ibogaine research, and a 2026 federal executive order directed psychedelic research support (Texas will launch its own clinical trials into ibogaine psychedelic after failing to find a drug company to help).
- Cost and accessibility: treatment is self-funded abroad or via grants; participants in one registered study bear all treatment costs (NCT07226570), and access is difficult where ibogaine is banned.
- Payer incentives: institutional payers may favor low-cost maintenance medications (methadone, buprenorphine), a potential structural bias in guidelines and funding; Texas required company partners to commit 20% of future drug revenue to the state (a Texas Tribune report).
Interaction with Foundational Habits
- Sleep: indirect and mixed. The prolonged session is followed by a residual stage of reduced sleep need, and 3% of veterans needed treatment for insomnia (Cherian et al., 2024); self-reported insomnia later improved (Davis et al., 2023).
- Nutrition: direct. Protocols require an 8-hour fast with an oral gastroprotective agent (stomach-lining protector) (Cherian et al., 2024), exclude grapefruit and other citrus (NCT05029401), and depend on normal potassium and magnesium status.
- Exercise: indirect. No exercise studies exist; ataxia lasting up to 24 hours precludes exertion around dosing, and sweat-induced electrolyte loss is a mechanistic concern for QT risk. Yoga and breathwork were offered on site (Cherian et al., 2024).
- Stress management: potentiating. Pre-treatment coaching and post-treatment integration are part of the Stanford program, and larger mystical experiences accompanied larger PTSD reductions (Brown et al., 2026); relapses followed home stressors (Cherian et al., 2024).
Monitoring Protocol & Defining Success
Baseline testing before any dosing establishes cardiac, electrolyte, liver, kidney and drug-metabolism status and documents the symptoms to be tracked. Published protocols require a 12-lead ECG, electrolyte and organ-function blood tests, a urine drug screen and, in some, CYP2D6 genotyping, plus a review of medications and supplements for interacting agents.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Resting QTc (12-lead ECG) | At or below 420 ms | Arrhythmia risk | Fridericia-corrected (a heart-rate correction formula); conventional limit below 450 ms (men) or 460 ms (women); measured at baseline, then continuously for 24+ hours; above 500 ms is high risk |
| Heart rate | 55–80 beats per minute | Bradycardia risk | Conventional 60–100; trials exclude below 50; monitored continuously after dosing |
| Blood pressure | Below 120/80 mmHg | Hypertension around dosing | Trials exclude 160/100 or higher; monitored during the session |
| Serum potassium | 4.0–5.0 mmol/L | Torsades risk | Conventional 3.5–5.0; morning draw, since delayed sample processing raises measured values; rechecked at dosing and 12–24 hours |
| Serum magnesium | 2.0–2.5 mg/dL | QT protection | Conventional 1.7–2.2; serum reflects little of total body magnesium, so red-cell magnesium is a paired test; rechecked after intravenous magnesium |
| Serum calcium | 9.2–10.0 mg/dL | QT effect of low calcium | Conventional 8.5–10.2; measured at baseline |
| ALT and AST | ALT and AST both below 25 U/L | Liver clearance | ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; conventional upper limit about 40; measured at baseline |
| eGFR | Above 90 mL/min/1.73 m² | Kidney clearance | eGFR (estimated glomerular filtration rate) reflects kidney filtering; conventional above 60; measured at baseline |
| CYP2D6 genotype | No established target; record phenotype | Sets exposure and dose | Protocols halve the dose in or exclude poor metabolizers; for other variants, change from own baseline is tracked |
| Urine drug screen | Negative for non-prescribed substances | Interactions, withdrawal seizures | Includes opioids, benzodiazepines, stimulants; also breath alcohol |
Ongoing monitoring follows the cadence used in published protocols: continuous ECG and blood pressure from dosing through at least 24 hours, because QTc stayed above 450 ms beyond 24 hours in 6 of 14 patients (Knuijver et al., 2022); electrolytes at dosing and again 12–24 hours later; then symptom and function reassessment at 4–5 days and 1 month, and every 3–6 months for durability tracking.
Qualitative markers include:
- Craving intensity and withdrawal comfort
- Mood, anxiety and trauma-symptom scores on validated questionnaires
- Sleep quality and duration
- Cognitive clarity, concentration and processing speed
- Gait and coordination recovery within 24 hours
- Energy and daily functioning
- Substance-use days and relapse triggers
Emerging Research
- Relevance to health-optimizing adults: all ibogaine trials found in a ClinicalTrials.gov registry search enroll people with addiction, PTSD or brain injury; none targets healthy adults or aging outcomes.
- Early-phase opioid withdrawal trial: NCT05029401, a Phase 1/2a study (safety, dosing and first efficacy test) with 116 participants, single-dose ibogaine versus placebo, completed January 2024; the sponsor, atai Therapeutics, develops ibogaine-based drugs, and results are not posted.
- Stanford magnesium-ibogaine study: NCT04313712, 30 veterans, active not recruiting; imaging follow-up reported thicker cortex and lower predicted brain age (Geoly et al., 2026).
- Brain imaging in opioid use disorder: NCT07226570, 20 participants, recruiting, will measure reward-circuit connectivity and brain chemistry after treatment abroad.
- Alcohol use disorder pilot: NCT03380728, 9 adults, completed; a matching nine-adult pilot reported reduced alcohol consumption but heart effects needing monitoring (Rocha et al., 2026).
- Methadone tapering trial: NCT04003948, Phase 2 study, sponsored by ICEERS (a nonprofit promoting iboga use), randomizing (assigning by chance) 20 patients to two ibogaine dosing schedules; completed, no results publication identified.
- Combined veterans study: NCT07717866, 52 veterans, observational (researchers do not assign treatment), ibogaine-magnesium plus 5-MeO-DMT and other therapies; active, not recruiting.
- State-funded Texas program: university-led trials funded by $50 million from the Legislature; no NCT ID was located (Texas will launch its own clinical trials into ibogaine psychedelic after failing to find a drug company to help).
- Genotype-guided dosing and safer analogues: CYP2D6-based dosing (Knuijver et al., 2024) and non-hallucinogenic analogues such as tabernanthalog (Cameron et al., 2021) could reduce risk, though analogues would not test ibogaine itself.
- Findings that could weaken the case: blinded trials (participants unaware of their treatment), overdose-risk concerns from addiction medicine, whose practitioners prescribe the competing medications (Terasaki et al., 2026) and heart-safety findings summarized in a narrative review (Brunt, 2026) could narrow the supportive evidence.
Conclusion
Ibogaine is a plant-derived compound given as a single, long, dream-like session. The human evidence for benefit is modest and comes from people with addiction, trauma-related conditions or brain injury, not from healthy adults pursuing longevity. The strongest signals are reduced trauma, mood and anxiety symptoms in veterans and eased opioid withdrawal, but these rest on small studies without comparison groups, and the one published comparison-group trial in opioid withdrawal involved a related compound and was inconclusive. One small comparison-group trial in cocaine dependence has not been replicated. Effects on brain structure are speculative. No evidence addresses lifespan.
The main risk is well documented: disturbances of heart rhythm, sometimes fatal, which can appear hours to days after dosing and are magnified by other drugs and by genetic differences in how the liver clears the compound. Loss of coordination, nausea and headache are common and short-lived. Protocols that add magnesium, screen for heart and psychiatric conditions, and monitor continuously address these risks, but they exist mainly in research or clinics abroad.
The evidence base is limited. Much of it comes from clinics that provide the treatment, companies developing ibogaine-based drugs and advocacy-funded researchers, all with a financial or mission interest; the main cautionary commentary comes from a field prescribing competing treatments, and some public funders tie support to a share of future revenue. The data are too limited to establish clinical use. Uncertainty remains high, and the balance of benefit and risk for healthy, risk-aware adults is undocumented.